Samsung Bioepis has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SBE303, an anticancer drug candidate based on antibody-drug conjugate (ADC) technology, the company said Wednesday. SBE303 is the first novel drug candidate in Samsung Bioepis' pipeline. It is an ADC, a type of biopharmaceutical drug designed to deliver powerful cancer-killing agents directly to cancer cells while minimizing damage to healthy tissues. ADCs are oftentimes referred to as "biological missiles" because of their targeted approach. SBE303 targets Nectin-4, a cell adhesion protein expressed in several types of cancer, including urothelial, lung and breast cancers. Existing ADCs targeting Nectin-4 face limitations because of their narrow therapeutic window, meaning the difference between an effective dose and a dose that causes serious side effects is relatively small. Samsung Bioepis designed SBE303 to address these limitations by combining an antibody that specifically targets Nectin-4 with a potent anticancer agent known as a topoisomerase I inhibitor, using its own linker